JP2019517572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517572A5 JP2019517572A5 JP2018564983A JP2018564983A JP2019517572A5 JP 2019517572 A5 JP2019517572 A5 JP 2019517572A5 JP 2018564983 A JP2018564983 A JP 2018564983A JP 2018564983 A JP2018564983 A JP 2018564983A JP 2019517572 A5 JP2019517572 A5 JP 2019517572A5
- Authority
- JP
- Japan
- Prior art keywords
- here
- chemotherapeutic agent
- naphthalen
- yloxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 12
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 4
- DGPGXHRHNRYVDH-UHFFFAOYSA-N 4-[2-(5-methyl-1-naphthalen-2-ylpyrazol-3-yl)oxyethyl]morpholine Chemical compound N=1N(C=2C=C3C=CC=CC3=CC=2)C(C)=CC=1OCCN1CCOCC1 DGPGXHRHNRYVDH-UHFFFAOYSA-N 0.000 claims 4
- 229960001756 oxaliplatin Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 229960001592 Paclitaxel Drugs 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- -1 isomer Substances 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 229930003347 taxol Natural products 0.000 claims 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 3
- SHRYQZBTQDMGLZ-UHFFFAOYSA-N 4-[2-(5-methyl-1-naphthalen-2-ylpyrazol-3-yl)oxyethyl]morpholine;hydrochloride Chemical compound Cl.N=1N(C=2C=C3C=CC=CC3=CC=2)C(C)=CC=1OCCN1CCOCC1 SHRYQZBTQDMGLZ-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940113083 morpholine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382258 | 2016-06-06 | ||
| EP16382258.8 | 2016-06-06 | ||
| PCT/EP2017/063614 WO2017211763A1 (en) | 2016-06-06 | 2017-06-05 | Use of sigma receptor ligands in cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517572A JP2019517572A (ja) | 2019-06-24 |
| JP2019517572A5 true JP2019517572A5 (zh) | 2020-07-16 |
| JP7094231B2 JP7094231B2 (ja) | 2022-07-01 |
Family
ID=56134287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564983A Active JP7094231B2 (ja) | 2016-06-06 | 2017-06-05 | がんにおけるシグマ受容体リガンドの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190142840A1 (zh) |
| EP (1) | EP3463339B1 (zh) |
| JP (1) | JP7094231B2 (zh) |
| CN (1) | CN109310672B (zh) |
| AR (1) | AR108682A1 (zh) |
| ES (1) | ES2969815T3 (zh) |
| TW (1) | TW201808300A (zh) |
| WO (1) | WO2017211763A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2576144C (en) | 2004-08-27 | 2012-12-11 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| GB0907973D0 (en) * | 2009-05-08 | 2009-06-24 | Modern Biosciences Plc | Combination therapy |
| EP2292236A1 (en) | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| RU2559325C2 (ru) | 2009-11-25 | 2015-08-10 | Лабораторьос Дель Др. Эстеве, С.А. | Соли 4-[2-[[5-метил-1-(2-нафталинил)-1н-пиразол-3-ил]окси]этил]морфолина |
| ES2586212T3 (es) | 2010-02-04 | 2016-10-13 | Laboratorios Del Dr. Esteve, S.A. | Polimorfos y solvatos de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oxi]etil]morfolina |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
-
2017
- 2017-06-05 JP JP2018564983A patent/JP7094231B2/ja active Active
- 2017-06-05 AR ARP170101529A patent/AR108682A1/es unknown
- 2017-06-05 CN CN201780034885.9A patent/CN109310672B/zh active Active
- 2017-06-05 WO PCT/EP2017/063614 patent/WO2017211763A1/en unknown
- 2017-06-05 EP EP17726968.5A patent/EP3463339B1/en active Active
- 2017-06-05 TW TW106118544A patent/TW201808300A/zh unknown
- 2017-06-05 US US16/306,946 patent/US20190142840A1/en not_active Abandoned
- 2017-06-05 ES ES17726968T patent/ES2969815T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015083580A5 (zh) | ||
| JP2019536805A5 (zh) | ||
| JP2017226708A5 (zh) | ||
| JP2012193216A5 (zh) | ||
| JP2019521180A5 (zh) | ||
| JP2020097577A5 (zh) | ||
| JP2013503174A5 (zh) | ||
| JP2016515628A5 (zh) | ||
| JP6014142B2 (ja) | Ｎ−ヒドロキシ−４−｛２−［３−（ｎ，ｎ−ジメチルアミノメチル）ベンゾフラン−２−イルカルボニルアミノ］エトキシ｝ベンズアミドの投与に関するスキーム | |
| NZ711179A (en) | Oral formulations of deferasirox | |
| JP2020523356A5 (zh) | ||
| JP2017014206A5 (zh) | ||
| JP2017508817A5 (zh) | ||
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| JP2019513812A5 (zh) | ||
| JP2019518022A5 (zh) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2018521007A5 (zh) | ||
| JP2019530706A5 (zh) | ||
| JP2014507412A5 (zh) | ||
| JP2012526090A (ja) | Ａｖｅ８０６２およびソラフェニブを含む抗腫瘍の組み合わせ | |
| JP2016515550A5 (zh) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JP2012527424A5 (zh) | ||
| JP2017516842A5 (zh) |